These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27980462)

  • 1. Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials.
    Kawai Y; Fuji T; Fujita S; Kimura T; Ibusuki K; Abe K; Tachibana S
    Thromb J; 2016; 14():48. PubMed ID: 27980462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V.
    Fuji T; Fujita S; Kawai Y; Nakamura M; Kimura T; Fukuzawa M; Abe K; Tachibana S
    Thromb J; 2015; 13():27. PubMed ID: 26269694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
    Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
    Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin.
    Fuji T; Ochi T; Niwa S; Fujita S
    J Orthop Sci; 2008 Sep; 13(5):442-51. PubMed ID: 18843459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery.
    Fuji T; Fujita S; Kawai Y; Nakamura M; Kimura T; Kiuchi Y; Abe K; Tachibana S
    Thromb Res; 2014 Jun; 133(6):1016-22. PubMed ID: 24680549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban or Enoxaparin.
    Ricket AL; Stewart DW; Wood RC; Cornett L; Odle B; Cluck D; Freshour J; El-Bazouni H
    Ann Pharmacother; 2016 Apr; 50(4):270-5. PubMed ID: 26783354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
    Feng W; Wu K; Liu Z; Kong G; Deng Z; Chen S; Wu Y; Chen M; Liu S; Wang H
    Thromb Res; 2015 Dec; 136(6):1133-44. PubMed ID: 26498222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.
    Fuji T; Wang CJ; Fujita S; Kawai Y; Kimura T; Tachibana S
    J Arthroplasty; 2014 Dec; 29(12):2439-46. PubMed ID: 25047458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthroplasty.
    Sasaki H; Ishida K; Shibanuma N; Tei K; Tateishi H; Toda A; Yamashiro Y; Matsumoto T; Kuroda R; Kurosaka M
    Int Orthop; 2014 Mar; 38(3):525-9. PubMed ID: 24100922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical benefit of graduated compression stockings for prevention of venous thromboembolism after total knee arthroplasty: post hoc analysis of a phase 3 clinical study of edoxaban.
    Fuji T; Fujita S; Kimura T; Ibusuki K; Abe K; Tachibana S; Nakamura M
    Thromb J; 2016; 14():13. PubMed ID: 27284271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty.
    Hur M; Park SK; Koo CH; Jung ED; Kang P; Kim WH; Kim JT; Jung CW; Bahk JH
    Acta Orthop; 2017 Dec; 88(6):634-641. PubMed ID: 28787226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.
    Turpie AG; Lassen MR; Eriksson BI; Gent M; Berkowitz SD; Misselwitz F; Bandel TJ; Homering M; Westermeier T; Kakkar AK
    Thromb Haemost; 2011 Mar; 105(3):444-53. PubMed ID: 21136019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
    Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
    Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
    Lassen MR; Fisher W; Mouret P; Agnelli G; George D; Kakkar A; Mismetti P; Turpie AG;
    J Thromb Haemost; 2012 May; 10(5):822-32. PubMed ID: 22429800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.
    Fuji T; Fujita S; Tachibana S; Kawai Y
    J Thromb Haemost; 2010 Nov; 8(11):2458-68. PubMed ID: 20723033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.
    Colwell CW; Berkowitz SD; Davidson BL; Lotke PA; Ginsberg JS; Lieberman JR; Neubauer J; McElhattan JL; Peters GR; Francis CW
    J Thromb Haemost; 2003 Oct; 1(10):2119-30. PubMed ID: 14521593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials.
    Eriksson BI; Dahl OE; Rosencher N; Clemens A; Hantel S; Feuring M; Kreuzer J; Huo M; Friedman RJ
    Thromb J; 2015; 13():36. PubMed ID: 26578849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
    Friedman RJ; Dahl OE; Rosencher N; Caprini JA; Kurth AA; Francis CW; Clemens A; Hantel S; Schnee JM; Eriksson BI;
    Thromb Res; 2010 Sep; 126(3):175-82. PubMed ID: 20434759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3).
    Eriksson BI; Agnelli G; Gallus AS; Lassen MR; Prins MH; Renfurm RW; Kashiwa M; Turpie AG
    Thromb Haemost; 2014 Feb; 111(2):213-25. PubMed ID: 24136153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.